Jubilant Biosys Limited, a wholly owned subsidiary of Jubilant Pharmova Limited, announced the opening of a new discovery and preclinical facility in Noida (Delhi NCR). With this expansion, the global CRDMO now operates five sites across India and Europe. It has doubled its overall chemistry capacity for discovery research and early-stage scale-up projects. This strategic investment strengthens the company’s ability to support growing client demand, particularly for fee-for-service (FFS) programs.
Integrated Discovery and Scale-Up Capabilities
The multimillion-dollar facility brings together discovery research and early-phase scale-up under one roof. It houses advanced R&D laboratories alongside two dedicated pilot plants, enabling faster project progression from concept to scalable processes. As demand for flexible and low-risk development models increases, the facility positions Jubilant Biosys to deliver integrated, end-to-end chemistry solutions more efficiently.
Accelerating Client Programs with Faster, Seamless Transfers
Giuliano Perfetti, CEO, Jubilant Biosys Limited, said, “With improving funding conditions, we expect even stronger demand next year. This new facility doubles our capabilities, allowing us to deliver discovery projects faster and seamlessly transfer them to our GMP facilities for IND filings and commercial phases”.
Strengthening the Noida Chemistry Innovation Ecosystem
The facility complements the company’s existing Chemistry Research Innovation Centre (CRIC) in Greater Noida. It creates a fully unified route from discovery to scale-up for biotech and pharma partners. Collectively, Jubilant Biosys now employs more than 1,300 scientists across its global operations. The Noida site adds multiple manufacturing lines and has already onboarded several new clients, reinforcing the company’s growth momentum.
Designed for Flexibility, Scale, and Future Expansion
Designed to handle batch sizes ranging from hundreds of grams to 25 kg, the small-molecule hub integrates two pilot plant blocks with co-located discovery laboratories. The facility features 20,000 sq ft of state-of-the-art R&D space and is equipped with 15 reactors, ranging from 20 litres to 250 litres. Importantly, the site has been engineered for future growth, with the potential to quadruple capacity as client requirements continue to expand.
Rising Demand Drives Strong Financial Performance
Jubilant Biosys works with 8 of the world’s top 20 pharmaceutical companies. Earlier this year, the company reported a 42% year-on-year increase in Q1 FY26 revenue from drug discovery projects, driven largely by rising demand for FFS contracts.
End-to-End Chemistry Services from a Single Campus
From the Noida campus, innovators gain access to a comprehensive suite of services. These include route scouting, process design and optimisation, and scalable synthesis development. Additional offerings include analytical support, salt screening, polymorph evaluation, and seamless technology transfer to pilot plants. As per the press release, these capabilities reinforce Jubilant Biosys’ position as a trusted partner. They help accelerate drug discovery and early development programs.
